Fragment-based Drug Discovery
A Global Strategic Business Report
MCP16405
WHAT'S BEHIND OUR DATA?
140857226
DOMAIN TRANSCRIPTS6080276
BRANDS TRACKED1729341
FEATURED COMPANIES22574
TOPICS COVERED82719
MARKET SEGMENTS91
KEY INDUSTRIES1574
CURATION TEAM4761909
DECISION MAKERSEXECUTIVE ENGAGEMENTS BY TIER (836)
56
CXO137
VICE PRESIDENT307
DIRECTOR270
MANAGER66
MARKETING
REQUEST FULL-STACK INDEX
Includes 350+ pages validated sources
QUESTIONNAIRE
EXECUTIVES
DATA ROOM
HIGHLIGHTS & REPORT INDEX
Global Fragment-based Drug Discovery Market to Reach US$1.6 Billion by 2030
The global market for Fragment-based Drug Discovery estimated at US$977.0 Million in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Fragment Optimization segment is estimated at 7.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$270.8 Million While China is Forecast to Grow at 8.2% CAGR
The Fragment-based Drug Discovery market in the U.S. is estimated at US$270.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$248.7 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.
Global Fragment-Based Drug Discovery Market - Key Trends & Drivers Summarized
Why Is Fragment-Based Drug Discovery a Game Changer in Pharmaceuticals?
Fragment-Based Drug Discovery (FBDD) has revolutionized pharmaceutical research by allowing scientists to develop drugs with higher specificity and efficacy. Unlike traditional drug discovery, FBDD involves screening smaller, “fragment” molecules that bind to target sites on proteins, which can then be optimized into potent drugs. This approach is particularly effective for complex disease targets such as cancer, where traditional methods have struggled. FBDD accelerates the drug discovery process and often leads to more viable drug candidates, making it a valuable approach for addressing unmet medical needs.
How Are Advanced Screening Techniques Enhancing FBDD?
The success of FBDD heavily relies on advanced screening technologies that enable the identification of fragment interactions with target proteins. Techniques like nuclear magnetic resonance (NMR), X-ray crystallography, and high-throughput screening allow researchers to visualize binding interactions in detail, facilitating more precise drug design. Recent advancements in AI-driven screening and computational modeling further optimize the FBDD process by predicting fragment-target binding more accurately. These innovations make FBDD a faster, more efficient, and cost-effective approach to drug discovery, appealing to pharmaceutical companies aiming for shorter development timelines.
What Role Does FBDD Play in Cancer and Neurological Research?
FBDD is particularly valuable in oncology and neurological research, where complex and traditionally “undruggable” targets are common. Cancer research, for example, benefits from FBDD’s ability to identify small molecule inhibitors that can precisely target and disrupt cancer cell growth mechanisms. Similarly, in neurological disorders, FBDD aids in discovering treatments that can cross the blood-brain barrier, addressing diseases like Alzheimer’s and Parkinson’s. The ability of FBDD to uncover novel therapeutic options for difficult-to-treat conditions makes it a growing area of focus in medical research.
What Drives Growth in the Fragment-Based Drug Discovery Market?
The growth in the FBDD market is driven by advancements in screening technologies, rising demand for targeted therapies, and its applications in challenging disease areas. New screening tools and AI-driven computational models enhance the efficiency of FBDD, attracting pharmaceutical companies looking for cost-effective drug discovery methods. The demand for targeted therapies, especially in oncology and neurology, further fuels FBDD adoption. Moreover, FBDD’s ability to identify novel treatment options for complex diseases provides a pathway for addressing unmet medical needs, making it a crucial area in modern pharmaceutical research.
SCOPE OF STUDY
The report analyzes the Fragment-based Drug Discovery market by the following Segments, and Geographic Regions/Countries:
Segments:
Technology (Fragment Screening, Fragment Optimization); End-Use (Biopharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..
SELECT PLAYERS
Akaal Pharma Pty. Ltd.; Algorae Pharmaceuticals Ltd.; Aragen Life Sciences Ltd.; Beactica Therapeutics AB; Carna Biosciences, Inc.; Charles River Laboratories International, Inc.; Crelux; Evotec SE; Marsala Biotech Inc.; PsychoGenics, Inc.
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy |
| How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind |
| How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind |
| Fragment-based Drug Discovery – Global Key Competitors Percentage Market Share in 2024 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2024 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Rising Demand for Faster and Cost-Effective Drug Discovery Methods |
| Increased Focus on Precision Medicine and Targeted Therapy Development |
| Technological Advancements in High-Throughput Screening and X-Ray Crystallography |
| Growth in Collaboration Between Pharmaceutical Companies and Academic Institutions |
| Expansion of Fragment-Based Drug Discovery for Oncology and CNS Disorders |
| Growing Adoption of Fragment-Based Approaches in Drug Design for Complex Diseases |
| Surge in Demand for Fragment Libraries with High Chemical Diversity |
| Increased Investment in Artificial Intelligence for Accelerating Drug Discovery |
| Expansion of Fragment-Based Drug Discovery in Rare and Orphan Diseases |
| Rising Use of Fragment-Based Techniques to Reduce Drug Toxicity and Side Effects |
| Growth in Biopharma R&D Spending on Novel Therapeutics Using Fragment-Based Methods |
| Demand for Software Tools and Platforms to Enhance Fragment-Based Research |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Fragment-based Drug Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030 |
| World Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Fragment Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Fragment Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Fragment Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Fragment Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Fragment Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Fragment Optimization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| USA Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| JAPAN |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| CHINA |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| EUROPE |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| FRANCE |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| GERMANY |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| UNITED KINGDOM |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| UK Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| ASIA-PACIFIC |
| Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of World Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Rest of World 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030 |
| Rest of World Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR |
| Rest of World Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR |
| Rest of World 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030 |
COMPETITIVE METRICS
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]